FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a fused protein binding to CD47 for transmitting a co-stimulating signal to a CD28 T-cell; it can be used in medicine.
EFFECT: fused protein consisting of a CD47 binding part SIRPα, a CD28 transmembrane part and a signal domain of a co-stimulating CD28 molecule can be used for creating T-cells for the effective immunotherapy of cancer expressing CD47.
51 cl, 13 dwg, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY AGAINST CD20 | 2017 |
|
RU2782699C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| COMBINATION OF ANTIBODY AGAINST HGFR AND HEGFR FOR TREATMENT OF TUMOR AND/OR METASTASIS | 2019 |
|
RU2788606C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
